Hypertension Control in Adults with Diabetes Mellitus and Recurrent Cardiovascular Events

Global Results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin

Ann Marie Navar, Dianne S. Gallup, Yuliya Lokhnygina, Jennifer B. Green, Darren K McGuire, Paul W. Armstrong, John B. Buse, Samuel S. Engel, John M. Lachin, Eberhard Standl, Frans Van De Werf, Rury R. Holman, Eric D. Peterson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Systolic blood pressure (SBP) treatment targets for adults with diabetes mellitus remain unclear. SBP levels among 12 275 adults with diabetes mellitus, prior cardiovascular disease, and treated hypertension were evaluated in the TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) randomized trial of sitagliptin versus placebo. The association between baseline SBP and recurrent cardiovascular disease was evaluated using multivariable Cox proportional hazards modeling with restricted cubic splines, adjusting for clinical characteristics. Kaplan-Meier curves by baseline SBP were created to assess time to cardiovascular disease and 2 potential hypotension-related adverse events: worsening kidney function and fractures. The association between time-updated SBP and outcomes was examined using multivariable Cox proportional hazards models. Overall, 42.2% of adults with diabetes mellitus, cardiovascular disease, and hypertension had an SBP ≥140 mm Hg. The association between SBP and cardiovascular disease risk was U shaped, with a nadir ≈130 mm Hg. When the analysis was restricted to those with baseline SBP of 110 to 150 mm Hg, the adjusted association between SBP and cardiovascular disease risk was flat (hazard ratio per 10-mm Hg increase, 0.96; 95% confidence interval, 0.91-1.02). There was no association between SBP and risk of fracture. Above 150 mm Hg, higher SBP was associated with increasing risk of worsening kidney function (hazard ratio per 10-mm Hg increase, 1.10; 95% confidence interval, 1.02-1.18). Many patients with diabetes mellitus have uncontrolled hypertension. The U-shaped association between SBP and cardiovascular disease events was largely driven by those with very high or low SBP, with no difference in cardiovascular disease risk between 110 and 150 mm Hg. Lower SBP was not associated with higher risks of fractures or worsening kidney function.

Original languageEnglish (US)
Pages (from-to)907-914
Number of pages8
JournalHypertension
Volume70
Issue number5
DOIs
StatePublished - Nov 1 2017

Fingerprint

Diabetes Mellitus
Blood Pressure
Hypertension
Cardiovascular Diseases
Sitagliptin Phosphate
Hematologic Diseases
Kidney
Hypotension
Confidence Intervals

Keywords

  • blood pressure
  • cardiovascular disease
  • diabetes mellitus
  • hypertension
  • hypotension

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Hypertension Control in Adults with Diabetes Mellitus and Recurrent Cardiovascular Events : Global Results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin. / Navar, Ann Marie; Gallup, Dianne S.; Lokhnygina, Yuliya; Green, Jennifer B.; McGuire, Darren K; Armstrong, Paul W.; Buse, John B.; Engel, Samuel S.; Lachin, John M.; Standl, Eberhard; Van De Werf, Frans; Holman, Rury R.; Peterson, Eric D.

In: Hypertension, Vol. 70, No. 5, 01.11.2017, p. 907-914.

Research output: Contribution to journalArticle

Navar, AM, Gallup, DS, Lokhnygina, Y, Green, JB, McGuire, DK, Armstrong, PW, Buse, JB, Engel, SS, Lachin, JM, Standl, E, Van De Werf, F, Holman, RR & Peterson, ED 2017, 'Hypertension Control in Adults with Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin', Hypertension, vol. 70, no. 5, pp. 907-914. https://doi.org/10.1161/HYPERTENSIONAHA.117.09482
Navar, Ann Marie ; Gallup, Dianne S. ; Lokhnygina, Yuliya ; Green, Jennifer B. ; McGuire, Darren K ; Armstrong, Paul W. ; Buse, John B. ; Engel, Samuel S. ; Lachin, John M. ; Standl, Eberhard ; Van De Werf, Frans ; Holman, Rury R. ; Peterson, Eric D. / Hypertension Control in Adults with Diabetes Mellitus and Recurrent Cardiovascular Events : Global Results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin. In: Hypertension. 2017 ; Vol. 70, No. 5. pp. 907-914.
@article{f96fa25b403240a68f6571d91d62a49f,
title = "Hypertension Control in Adults with Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin",
abstract = "Systolic blood pressure (SBP) treatment targets for adults with diabetes mellitus remain unclear. SBP levels among 12 275 adults with diabetes mellitus, prior cardiovascular disease, and treated hypertension were evaluated in the TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) randomized trial of sitagliptin versus placebo. The association between baseline SBP and recurrent cardiovascular disease was evaluated using multivariable Cox proportional hazards modeling with restricted cubic splines, adjusting for clinical characteristics. Kaplan-Meier curves by baseline SBP were created to assess time to cardiovascular disease and 2 potential hypotension-related adverse events: worsening kidney function and fractures. The association between time-updated SBP and outcomes was examined using multivariable Cox proportional hazards models. Overall, 42.2{\%} of adults with diabetes mellitus, cardiovascular disease, and hypertension had an SBP ≥140 mm Hg. The association between SBP and cardiovascular disease risk was U shaped, with a nadir ≈130 mm Hg. When the analysis was restricted to those with baseline SBP of 110 to 150 mm Hg, the adjusted association between SBP and cardiovascular disease risk was flat (hazard ratio per 10-mm Hg increase, 0.96; 95{\%} confidence interval, 0.91-1.02). There was no association between SBP and risk of fracture. Above 150 mm Hg, higher SBP was associated with increasing risk of worsening kidney function (hazard ratio per 10-mm Hg increase, 1.10; 95{\%} confidence interval, 1.02-1.18). Many patients with diabetes mellitus have uncontrolled hypertension. The U-shaped association between SBP and cardiovascular disease events was largely driven by those with very high or low SBP, with no difference in cardiovascular disease risk between 110 and 150 mm Hg. Lower SBP was not associated with higher risks of fractures or worsening kidney function.",
keywords = "blood pressure, cardiovascular disease, diabetes mellitus, hypertension, hypotension",
author = "Navar, {Ann Marie} and Gallup, {Dianne S.} and Yuliya Lokhnygina and Green, {Jennifer B.} and McGuire, {Darren K} and Armstrong, {Paul W.} and Buse, {John B.} and Engel, {Samuel S.} and Lachin, {John M.} and Eberhard Standl and {Van De Werf}, Frans and Holman, {Rury R.} and Peterson, {Eric D.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.117.09482",
language = "English (US)",
volume = "70",
pages = "907--914",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Hypertension Control in Adults with Diabetes Mellitus and Recurrent Cardiovascular Events

T2 - Global Results from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin

AU - Navar, Ann Marie

AU - Gallup, Dianne S.

AU - Lokhnygina, Yuliya

AU - Green, Jennifer B.

AU - McGuire, Darren K

AU - Armstrong, Paul W.

AU - Buse, John B.

AU - Engel, Samuel S.

AU - Lachin, John M.

AU - Standl, Eberhard

AU - Van De Werf, Frans

AU - Holman, Rury R.

AU - Peterson, Eric D.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Systolic blood pressure (SBP) treatment targets for adults with diabetes mellitus remain unclear. SBP levels among 12 275 adults with diabetes mellitus, prior cardiovascular disease, and treated hypertension were evaluated in the TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) randomized trial of sitagliptin versus placebo. The association between baseline SBP and recurrent cardiovascular disease was evaluated using multivariable Cox proportional hazards modeling with restricted cubic splines, adjusting for clinical characteristics. Kaplan-Meier curves by baseline SBP were created to assess time to cardiovascular disease and 2 potential hypotension-related adverse events: worsening kidney function and fractures. The association between time-updated SBP and outcomes was examined using multivariable Cox proportional hazards models. Overall, 42.2% of adults with diabetes mellitus, cardiovascular disease, and hypertension had an SBP ≥140 mm Hg. The association between SBP and cardiovascular disease risk was U shaped, with a nadir ≈130 mm Hg. When the analysis was restricted to those with baseline SBP of 110 to 150 mm Hg, the adjusted association between SBP and cardiovascular disease risk was flat (hazard ratio per 10-mm Hg increase, 0.96; 95% confidence interval, 0.91-1.02). There was no association between SBP and risk of fracture. Above 150 mm Hg, higher SBP was associated with increasing risk of worsening kidney function (hazard ratio per 10-mm Hg increase, 1.10; 95% confidence interval, 1.02-1.18). Many patients with diabetes mellitus have uncontrolled hypertension. The U-shaped association between SBP and cardiovascular disease events was largely driven by those with very high or low SBP, with no difference in cardiovascular disease risk between 110 and 150 mm Hg. Lower SBP was not associated with higher risks of fractures or worsening kidney function.

AB - Systolic blood pressure (SBP) treatment targets for adults with diabetes mellitus remain unclear. SBP levels among 12 275 adults with diabetes mellitus, prior cardiovascular disease, and treated hypertension were evaluated in the TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) randomized trial of sitagliptin versus placebo. The association between baseline SBP and recurrent cardiovascular disease was evaluated using multivariable Cox proportional hazards modeling with restricted cubic splines, adjusting for clinical characteristics. Kaplan-Meier curves by baseline SBP were created to assess time to cardiovascular disease and 2 potential hypotension-related adverse events: worsening kidney function and fractures. The association between time-updated SBP and outcomes was examined using multivariable Cox proportional hazards models. Overall, 42.2% of adults with diabetes mellitus, cardiovascular disease, and hypertension had an SBP ≥140 mm Hg. The association between SBP and cardiovascular disease risk was U shaped, with a nadir ≈130 mm Hg. When the analysis was restricted to those with baseline SBP of 110 to 150 mm Hg, the adjusted association between SBP and cardiovascular disease risk was flat (hazard ratio per 10-mm Hg increase, 0.96; 95% confidence interval, 0.91-1.02). There was no association between SBP and risk of fracture. Above 150 mm Hg, higher SBP was associated with increasing risk of worsening kidney function (hazard ratio per 10-mm Hg increase, 1.10; 95% confidence interval, 1.02-1.18). Many patients with diabetes mellitus have uncontrolled hypertension. The U-shaped association between SBP and cardiovascular disease events was largely driven by those with very high or low SBP, with no difference in cardiovascular disease risk between 110 and 150 mm Hg. Lower SBP was not associated with higher risks of fractures or worsening kidney function.

KW - blood pressure

KW - cardiovascular disease

KW - diabetes mellitus

KW - hypertension

KW - hypotension

UR - http://www.scopus.com/inward/record.url?scp=85031786481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031786481&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.117.09482

DO - 10.1161/HYPERTENSIONAHA.117.09482

M3 - Article

VL - 70

SP - 907

EP - 914

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 5

ER -